Shannon N. Westin, MD, MPH, FACOG

Articles

Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer

November 10th 2022

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

Antibody-Drug Conjugates in Ovarian Cancer Treatment

November 4th 2022

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

November 4th 2022

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

PARP Inhibitor Resistance in Ovarian Cancer Treatment

October 27th 2022

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment

October 27th 2022

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

The Rationale for PARP Inhibition plus IO in Ovarian Cancer

October 20th 2022

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

October 20th 2022

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial

October 17th 2022

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.

PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer

October 17th 2022

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial

October 6th 2022

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

Recent Updates in PARP Inhibitor Indications for Ovarian Cancer

October 6th 2022

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Novel Combinations for the Treatment of Advanced EC

May 19th 2021

Experts in gynecologic oncology discuss novel combination strategies for the treatment of advanced endometrial cancer.

Emerging Data From Ongoing IO Combination Trials in EC

May 19th 2021

Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.

Patient Selection for Lenvatinib-Pembrolizumab for Advanced EC

May 12th 2021

Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.

Impact of Lenvatinib-Pembrolizumab on Clinical Practice in Advanced EC

May 12th 2021

Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.

Safety Results From KEYNOTE-775 Trial in Advanced EC

May 4th 2021

Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.

Phase 3 KEYNOTE-775 Trial in Advanced Endometrial Cancer

May 4th 2021

Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.

Upcoming Clinical Trials for Ovarian Cancer

July 20th 2020

Emerging Therapies in Recurrent Ovarian Cancer

July 20th 2020

Antibody Drug Conjugates for Ovarian Cancer

July 20th 2020